ADMA

ADMA Biologics ranks top 12% on fundamentals and top 13% on price trend

A person in a white coat and blue gloves uses a pipette on a small glass vial on a metal counter. Trays of similar vials sit beside it, with large stainless steel machinery and bright windows illuminated by daylight in the background.

By StockLens

October 8, 2026

1 min read

A synthesis of StockLens's multi-domain algorithmic analysis.

Solid

ADMA

ADMA Biologics, Inc.

Source as of October 8, 2026

Domain Read

Fundamental

Exceptional domain read

Technical

Exceptional domain read

Risk

Exceptional domain read

Sentiment

Mixed Signals domain read

Macro

Mixed Signals domain read

Key takeaways

Operating margin is 42.3% and net profit margin 33.0% over the trailing twelve months, with the operating margin above the 21.7% upper-quartile mark of its peer group of 84 global mid-cap companies in biotechnology.
Shares are up 9.4% over the last 63 trading sessions (adjusted closes through Oct 7, 2026).
Return on invested capital is 28.7% over the trailing twelve months, above the 20.8% top-decile mark of its peer group of 107 global mid-cap companies in biotechnology.

ADMA Biologics' overall StockLens score ranks in the top 2%, with strength in both fundamentals (top 12%) and price trend (top 13%). The ranks cover the 2,156 US-listed companies StockLens analyzed on Oct 8, 2026.

How StockLens scores: every company is scored by the same quantitative engine across five domains (Fundamental, Technical, Risk, Sentiment, Macro), combined into one composite and read through the archetype lens that fits its business model.

This is not investment advice; it is an algorithmically generated analysis produced by StockLens's quantitative and agentic AI models.

Sources

Scores and grades reflect StockLens's proprietary model, as of October 8, 2026.

How StockLens reads ADMA Biologics, Inc.

Core Tension

Signal tension

High Growth Negative Margins: High-growth classification conflicts with negative/deteriorating margins

Tempered factor

Current Ratio: Mitigated: Strong liquidity: Operating Cash Flow to Current Liabilities > 0.4

Tempered factor

Interest Coverage: Mitigated: Strong cash interest service: operating cash flow covers interest expense more than 2x with positive free cash flow

Tempered factor

Equity Dilution: Mitigated: Justified dilution: Positive Free Cash Flow Growth AND Share Count Growth < 10%

Uncertainty

Sentiment carries lower confidence than the headline read.

Analyze ADMA in StockLens

Run a fresh StockLens analysis of ADMA Biologics, Inc. (ADMA).

ADMA Biologics ranks top 12% on fundamentals and top 13% on price trend

ADMA Biologics, Inc.

Domain Read

Key takeaways

Sources

Core Tension

Uncertainty

Analyze ADMA in StockLens

Tags